Variants can alter the virus's surface proteins, particularly the spike protein in the case of SARS-CoV-2. These changes can reduce the ability of antibodies generated by vaccines to neutralize the virus. Ongoing research and real-world data are essential to assess vaccine efficacy against new variants and guide potential updates to vaccine formulations.